- 1. g/m2
- [A metric unit of areal density equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit. ( NCI )] (UMLS (NCI) C1300564) Gram per Meter Squared;
Gram per Square Meter;
Gram Per Square Metre;
gsm =Quantitative Concept | - 19. GM-CSF/IL-2/MOAB 14G2A
- (UMLS (NCI) C0281368) =Therapeutic or Preventive Procedure
|
- 2. g/m3
- [The metric unit of mass concentration defined as the concentration of one gram of a substance in unit volume of the mixture equal to one cubic meter. The concept also refers to the metric unit of mass density (volumic mass) defined as the density of substance which mass equal to one gram occupies the volume one cubic meter. ( NCI )] (UMLS (NCI) C0439268) =Quantitative Concept
| - 20. GM-CSF/IL-2/MOAB 3622W94
- (UMLS (NCI) C0677997) =Therapeutic or Preventive Procedure
|
- 3. g/mL
- [A unit of mass concentration defined as the concentration of one kilogram of a substance in unit volume of the mixture equal to one liter. The concept also refers to the unit of mass density (volumic mass) defined as the density of substance which mass equal to one kilogram occupies the volume one liter. ( NCI )] (UMLS (NCI) C1300565) Gram per Milliliter;
kg/L;
Kilogram per Liter;
Kilogram Per Litre;
kilogram(s)/litre;
mg/mcl;
mg/uL;
Microgram per Nanoliter;
Milligram per Microliter;
ug/nL =Quantitative Concept | - 21. GM-CSF/IL-2/VBL
- (UMLS (NCI) C0677982) =Therapeutic or Preventive Procedure
|
- 4. GM-CSF plasmid DNA melanoma vaccine
- [A vaccine adjuvant consisting of a plasmid DNA encoding sargramostim (a granulocyte macrophage-colony stimulating factor). Upon administration, expressed sargramostim may stimulate a cytotoxic T cell response enhancing the host immune response to a concomitantly administered melanoma vaccine. ( NCI )] (UMLS (NCI) C0393071) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 22. GM-CSF/IL-6
- (UMLS (NCI) C0281625) =Therapeutic or Preventive Procedure
|
- 5. GM-CSF plasmid DNA pancreatic tumor cell vaccine
- [A whole cell vaccine comprised of irradiated allogenic pancreatic tumor cells transfected with a plasmid DNA encoding human sargramostim (GM-CSF). Vaccination results in expression of GM-CSF, which induces proliferation and differentiation hematopoietic lineage cells as well as stimulating macrophage and dendritic cell functions in antigen presentation and antitumor cell-mediated immunity. Furthermore, administration of this pancreatic tumor cell vaccine may elicit a cytotoxic T lymphocyte (CTL) response against similar host tumor cells, resulting in decreased tumor growth. ( NCI )] (UMLS (NCI) C0677758) =Pharmacologic Substance; Immunologic Factor ;
| - 23. GM-CSF/IL3 Fusion Protein
- [A recombinant fusion protein derived from the coding sequences of two growth factors, interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Milodistim exhibits greater receptor binding affinity and colony stimulating activity than its parent cytokines. This agent stimulates proliferation of immature hematopoietic cells and allows the stimulation and expansion of multi-lineage hematopoiesis from immature bone marrow progenitor cells. (NCI04) ( NCI )] (UMLS (NCI) C0211169) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
|
- 6. GM-CSF plasmid DNA sarcoma vaccine
- [An autologous sarcoma cell vaccine with potential immunostimulatory activity. Tumor cells harvested from a patient with sarcoma are transfected with a plasmid DNA encoding for human sargramostim (GM-CSF) using a particle-mediated gene transfer (PMGT) technique, which avoids the use infectious components. Vaccination with an autologous sargramostim sarcoma vaccine produces high levels of GM-CSF, a cytokine that enhances antigen presentation by activated macrophages and increases the recognition of weakly immunogenic tumors by cytotoxic T-lymphocytes. ( NCI )] (UMLS (NCI) C0393070) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 24. GM-CSF/L-PAM
- (UMLS (NCI) C0279312) =Therapeutic or Preventive Procedure
|
- 7. GM-CSF/gp100/IFA
- (UMLS (NCI) C0677818) =Therapeutic or Preventive Procedure
| - 25. GM-CSF/MOAB 3F8
- (UMLS (NCI) C0281630) =Therapeutic or Preventive Procedure
|
- 8. GM-CSF/GP100/IFA/MART-1/TYRP
- (UMLS (NCI) C0677812) =Therapeutic or Preventive Procedure
| - 26. GM-CSF/MOAB R24
- (UMLS (NCI) C0280903) =Therapeutic or Preventive Procedure
|
- 9. GM-CSF/IFA/TRP-1
- (UMLS (NCI) C0677822) =Therapeutic or Preventive Procedure ;
| - 27. GM-CSF/NM/PCB/PRED/VCR
- (UMLS (NCI) C0280639) =Therapeutic or Preventive Procedure
|
- 10. GM-CSF/IFA/TYRP
- (UMLS (NCI) C0677819) =Therapeutic or Preventive Procedure
| - 28. GM-CSF/PRED/VCR
- (UMLS (NCI) C0279310) =Therapeutic or Preventive Procedure
|
- 11. GM-CSF/IFA/VHL peptide
- (UMLS (NCI) C0796339) Incomplete Freund's Adjuvant/Sargramostim/Von Hippel-Lindau Peptide Vaccine;
=Therapeutic or Preventive Procedure | - 29. GM-CSF/PXT
- (UMLS (NCI) C0280939) =Therapeutic or Preventive Procedure
|
- 12. GM-CSF/IFN-A
- (UMLS (NCI) C0796391) Interferon Alfa/Sargramostim;
=Therapeutic or Preventive Procedure | - 30. GM-CSF/TNF
- (UMLS (NCI) C0281569) =Therapeutic or Preventive Procedure ;
|
- 13. GM-CSF/IFN-A/IL-2
- (UMLS (NCI) C0796334) Interferon Alfa/Interleukin-2/Sargramostim;
=Therapeutic or Preventive Procedure | - 31. GM-CSF/TSPA
- (UMLS (NCI) C0214035) =Therapeutic or Preventive Procedure
|
- 14. GM-CSF/IFN-A/ZDV
- (UMLS (NCI) C0338086) =Therapeutic or Preventive Procedure
| - 32. GM-CSF/ZDV
- (UMLS (NCI) C0279293) =Therapeutic or Preventive Procedure ;
|
- 15. GM-CSF/IFN-G
- (UMLS (NCI) C0280713) =Therapeutic or Preventive Procedure ;
| - 33. GM2-KLH
- [A substance used to stimulate the production of antibodies that fight certain cancer cells. ( NCI )] (UMLS (NCI) C0281208) =Lipid; Pharmacologic Substance; Immunologic Factor
|
- 16. GM-CSF/IFN-G/IL-1B/IL-2/TNF
- (UMLS (NCI) C0392981) =Therapeutic or Preventive Procedure
| - 34. GM2-KLH Vaccine/Interferon Alfa
- (UMLS (NCI) C0338325) =Therapeutic or Preventive Procedure ;
|
- 17. GM-CSF/IL-11
- (UMLS (NCI) C0678045) =Therapeutic or Preventive Procedure ;
| - 35. GM2-KLH Vaccine/QS21
- [A cancer vaccine based on the immunogenic ganglioside GM2, The GM2-KLH Vaccine/QS21 vaccine consists of GM2 conjugated with KLH keyhole limpet hemocyanin (KLH), a potent immunostimulant, and is admixed with the adjuvant QS21, a saponin fraction extracted from the bark of the South American tree Quillaja saponaria Molina. GM2 is a cell surface carbohydrate antigen expressed by most melanoma cells and various other tumor cell types. (NCI04) ( NCI )] (UMLS (NCI) C0338324) =Therapeutic or Preventive Procedure ;
|
- 18. GM-CSF/IL-2
- (UMLS (NCI) C0280714) =Therapeutic or Preventive Procedure ;
| - 36. GMP
- [guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. ( CSP )] (UMLS (CSP) C0520462) =Nucleic Acid, Nucleoside, or Nucleotide; Biologically Active Substance ;
=guanine nucleotide;
=cGMP |
home
